Solid Biosciences (SLDB) shares were up almost 34% in Tuesday trading after the company said a phase 1/2 trial of its gene therapy candidate SGT-003 for Duchenne muscular dystrophy yielded positive data.
Preliminary 90-day biopsy results from the initial three participants demonstrated a mean microdystrophin expression level of 110%, as assessed by western blot analysis, the company said. There were also enhancements in multiple biomarkers that point to improved muscle health and resilience, it added.
SGT-003 also demonstrated a favorable safety profile in six dosed participants, with no serious events reported, Solid said. The company plans to seek a meeting with the US Food and Drug Administration in mid-2025 to discuss SGT-003's potential for accelerated approval.
Separately, the company priced an underwritten offering of more than 35.7 million common shares at $4.03 apiece and prefunded warrants to purchase nearly 13.9 million common shares at $4.029 per warrant to raise about $200 million.
The offering is set to close on Wednesday, it said.
Price: 5.39, Change: +1.36, Percent Change: +33.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.